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Abstract In rat pheochromocytoma cell line (PC12) cells,
initial epidermal growth factor (EGF)-stimulated extracellular
signal-regulated protein kinases 1/2 (ERK1/2) phosphorylation
was similar to that promoted by nerve growth factor (NGF), but
declined rapidly. Pre-treatment with apigenin or LY294002
sustained EGF-stimulated ERK1/2 phosphorylation whereas
wortmannin partially blocked initial ERK1/2 phosphorylation.
Changes in ERK1/2 phosphorylation correlated with alterations
in p90 ribosomal S6 kinase activity. Wortmannin, LY294002 and
apigenin totally blocked growth factor-induced protein kinase B
phosphorylation. However, none of them potentiated Raf
activation, which was in fact decreased by LY290042 and
wortmannin. The sustained EGF-induced ERK1/2 activation
promoted by apigenin was not sufficient to commit PC12 cells to
differentiate, which was achieved by stimulation with NGF,
either alone or in the presence of apigenin. ß 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Epidermal growth factor (EGF) and nerve growth factor
(NGF) are potent activators of the classical extracellular sig-
nal-regulated protein kinases 1/2 (ERK1/2) (or p42/p44 MAP
kinases) pathway in the rat pheochromocytoma cell line
(PC12) cells [1]. However, EGF leads to stimulation of pro-
liferation whereas NGF induces PC12 di¡erentiation to a neu-
rone-like phenotype. The temporality of ERK1/2 activation,
very transient for EGF and sustained for several hours by
NGF, seems to act as a crucial decision point for the cell
commitment towards a speci¢c fate [1]. Di¡erential e¡ects of
EGF and NGF via Ras and Rap1 on protein kinase Raf
isotypes [2], and the requirement of the phosphoinositide
3-kinase (PI3K) pathway [3] have been reported to be in-
volved in the activation of ERK1/2 evoked by NGF. None-
theless, protein kinase B (PKB) (or Akt), one of the best
known downstream transmitters of PI3K-dependent e¡ects,
has been recently shown to phosphorylate c-Raf-1 and, spe-
cially, B-Raf on inhibitory sites [4,5]. Thus, it was conceivable
that activation of PKB might result in the deactivation of the
Raf/mitogen-activated protein kinase (MAPK)/ERK kinase/
ERK (Raf/MEK/ERK) pathway.
The fungal metabolite wortmannin, and the polyphenolic
compounds LY294002 and apigenin are two types of cell-per-
meant pharmacological inhibitors of PI3K [6^8]. Wortmannin
is e¡ective in the nanomolar range and causes the irreversible,
covalent modi¢cation of lysine-802 of the PI3K catalytic sub-
unit [6], whereas LY294002 and apigenin compete for the
ATP-binding domain in a reversible manner with IC50 values
in the micromolar range [7,8]. Under some circumstances,
wortmannin and LY294002 have been proving to block the
ERK1/2 activation pathway in some cell lines [9,10], but their
e¡ectiveness in blocking NGF induction of PC12 di¡erentia-
tion is more controversial [11,12]. Regarding the e¡ects of
apigenin on cell di¡erentiation, it has been shown that this
compound promoted neurite outgrowth and di¡erentiation of
B104 rat neuronal cells [13], but in contrast, interfered with
the expression of myo¢broblast phenotype in cultured human
embryonic lung ¢broblast IMR-90 [14]. Furthermore, apige-
nin had also been reported to inhibit ERK1/2 activation in
rapid proliferating cells [15] but it seems to have little e¡ect on
IMR-90 lung ¢broblasts [14]. In this work we studied the
in£uence of wortmannin, LY294002 and apigenin on the
ERK1/2 activation pathway promoted by EGF in PC12 cells,
and their e¡ects on neurite outgrowth as compared to that
promoted by NGF.
2. Materials and methods
2.1. Reagents and antibodies
NGF and EGF were purchased from Life Technologies, apigenin
from Sigma, wortmannin and LY294002 from Calbiochem. Protein
G-Sepharose, glutathione-Sepharose, [Q-32P]ATP and ECL were from
Amersham-Pharmacia. Anti-ERK1/2 (1 Wg/ml), anti-phospho-PKBK
(Ser473) (1 Wg/ml) and anti-rsk2 antibodies (2.5 Wg/200 Wg protein
sample) were from Upstate Biotech. Anti-phospho-MAPK (1/2000)
was from New England Biolabs. Anti-pan-Ras antibody OP40 was
from Oncogene Sciences (1/100) and anti-Raf-1 antibody (2.5 Wg/200
Wg protein sample), from Transduction Laboratories. Tissue culture
reagents were from Gibco.
2.2. Culture of PC12 cells and preparation of lysates
PC12 cells were cultured at 37‡C in a 95/5 air/CO2 water saturated
atmosphere in 75 cm2 collagen-coated £asks in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) containing 10% heat-inactivated horse se-
0014-5793 / 02 / $22.00 ß 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 3 2 5 2 - 5
*Corresponding author. Fax: (34)-93-5812006.
E-mail address: nestor.gomez@uab.es (N. Go¤mez).
Abbreviations: EGF, epidermal growth factor; ERK1/2, extracellular
signal-regulated protein kinases 1/2; MAPK, mitogen-activated pro-
tein kinase; MEK, MAPK/ERK kinase; MBP, myelin basic protein;
NGF, nerve growth factor; p90rsk, p90 ribosomal S6 kinase; PC12,
rat pheochromocytoma cell line; PI3K, phosphoinositide 3-kinase;
PKB, protein kinase B; RBD, Ras-binding domain of Raf-1
FEBS 25634 9-1-02
FEBS 25634 FEBS Letters 510 (2002) 149^153
rum, 5% heat-inactivated foetal bovine serum, 2 mM L-glutamine, 100
U/ml penicillin and 100 Wg/ml streptomycin. For treatments, the cells
were transferred to 60 mm collagen-coated dishes (3U106 cells per
dish) or to 100 mm dishes (107 cells per dish). After 48 h the cells were
starved in DMEM overnight and treated with NGF (50 ng/ml) or
EGF (100 ng/ml). When used, inhibitors were added to the dishes
5 min before the stimulation with growth factors. Cells were harvested
at the indicated times, washed with cold PBS and lysed with bu¡er A
(50 mM Tris^HCl, pH 7.5, 0.27 M sucrose, 1 mM EGTA, 1 mM
EDTA, 50 mM NaF, 1 mM sodium orthovanadate, 10 mM Na
L-glycerolphosphate, 5 mM PPi, 1% Triton X-100, 1 mM benzami-
dine, 1 mM phenylmethylsulfonyl£uoride (PMSF), and 0.1% (v/v) 2-
mercaptoethanol) for ERK1/2 and p90 ribosomal S6 kinase (p90rsk)
assays or with REB bu¡er (30 mM Tris-HCl, pH 7.5, 100 mM NaCl,
0.1 mM EDTA, 1% Triton X-100, 10% glycerol, 5 mM NaF, 0.2 mM
sodium orthovanadate, 0.3% (v/v) L-mercaptoethanol, 1 mM benza-
midine and 0.1 mM PMSF) for Ras and Raf assays. After 15 min on
ice the lysate was removed and centrifuged at 13 000Ug during 15 min
at 4‡C. Supernatants were used for Western blotting or immunopre-
cipitation.
2.3. Western blot analysis
The protein content of cellular extracts was quanti¢ed by Bradford
assay [16]. For Western blot experiments 50 Wg of protein were loaded
on SDS^PAGE gels and transferred onto PVDF membranes. The
membranes were incubated with the antibodies at the indicated con-
centrations and developed using the enhanced chemiluminescence re-
agent (ECL).
2.4. Immunocomplex p90rsk activity assays
Protein G-Sepharose (5 Wl bed volume) washed twice with bu¡er A
was incubated for 30 min at 4‡C with 2.5 Wg of anti-p90rsk antibody
and washed twice with bu¡er A plus 0.5 M NaCl and twice with
bu¡er A. Then, 200 Wg of cell extracts were added, and incubated
for 1 h at 4‡C under vigorous shaking. The beads were washed twice
with bu¡er A plus 0.5 M NaCl, twice with bu¡er A and once with
kinase bu¡er (50 mM Tris^HCl, pH 7.5, 1 mM EGTA and 2.5 mM
Mg-acetate). p90rsk activity in the immunoprecipitate was measured
using the synthetic peptide crosstide (GRPRTSSFAEG) at a ¢nal
concentration of 30 WM and 100 WM [Q-32P]ATP in a ¢nal volume
of 50 Wl. Phosphorylation was carried out for 30 min at 30‡C, and
then 40 Wl of the mixture was spotted on a P81 Whattman paper. The
papers were washed ¢ve times with 0.5% orthophosphoric acid, once
with acetone and air dried. Radioactivity was quanti¢ed in a scintil-
lation counter.
2.5. Measurement of Ras activation
The ability of Ras-GTP to bind to RBD (Ras-binding domain of
Raf-1) was used to analyse the amount of active Ras. Cells lysates (2.5
mg) were incubated with 75 Wg of GST-RBD bound to glutathione-
Sepharose beads for 2 h at 4‡C. Beads were washed four times with
REB bu¡er. Bound proteins were eluted by the addition of 25 Wl of
Laemmli loading bu¡er and immunoblotted with pan-Ras antibody as
described above. 50 Wg of cell lysates were also analysed to ensure
equal quantities of Ras in the assay.
2.6. Raf immunoprecipitation and kinase assay
Cell extracts (200 Wg) were incubated with 2.5 Wg of anti-Raf-1
antibody prebound to 20 Wl of protein G-Sepharose beads for 2 h
at 4‡C. The anti-Raf-coated beads were washed once with bu¡er B (20
mM Tris^HCl, pH 7.5, 100 mM NaCl, 2 mM EDTA, 5 mM MgCl2,
1% Triton X-100, 5 mM NaF, 10% glycerol, 0.5% (v/v) L-mercapto-
ethanol, 1 mM benzamidine and 0.1 mM PMSF) plus 1 M KCl, once
with bu¡er B plus 100 mM KCl and once with bu¡er B. The immu-
noprecipitates were resuspended in 20 Wl of bu¡er C (30 mM Tris^
HCl, pH 7.5, 0.1 mM EDTA, 0.3% (v/v) L-mercaptoethanol, 10 mM
MgCl2, 0.1% Triton X-100, 5 mM NaF, 0.2 mM sodium orthovana-
date) containing 0.8 mM ATP, 10 Wg/ml GST-MEK and 100 Wg/ml
GST-ERK2 and incubated for 30 min at 30‡C on a shaking platform.
The reaction was stopped by addition of 20 Wl of KILL bu¡er (30
mM Tris^HCl, pH 7.5, 6 mM EDTA, 0.3% (v/v) L-mercaptoethanol,
0.1% Triton X-100, 5 mM NaF and 0.2 mM sodium orthovanadate).
The samples were centrifuged at 13 000Ug for 1 min and 6 Wl aliquots
of the supernatant were added to 24 Wl of myelin basic protein (MBP)
bu¡er (50 mM Tris^HCl, pH 7.5, 0.1 mM EDTA, 0.3% (v/v) L-mer-
captoethanol, 10 mM MgCl2, 0.1% Triton X-100, 5 mM NaF, 0.2
mM sodium orthovanadate and 0.1 mM [Q-32P]ATP (400 000 cpm/
nmol), 2 mg/ml bovine serum albumin and 0.5 mg/ml MBP). After
15 min incubation at 30‡C, 24 Wl of the mixture was spotted on a P81
Whattman paper and the incorporation of phosphate into MBP de-
termined as in the p90rsk assay.
2.7. Detection of cellular di¡erentiation
Cells were plated at a density of 3U105 cells/60 mm dish and the
next day were treated with either NGF, EGF with or without the
Fig. 1. Apigenin and LY294002 sustained the phosphorylation of
MAP kinase activated by EGF. A: PC12 cells were serum starved
overnight and then treated with 50 ng/ml NGF or 100 ng/ml EGF
for the indicated times. B: Serum-starved PC12 cells were untreated
or treated with either 40 WM apigenin, 50 WM LY294002 or 100
nM wortmannin for 5 min before stimulation with 100 ng/ml EGF.
ERK1/2 were detected using an antibody against dual phosphorylat-
ed/activated forms of ERK (upper panel). In order to check that
the same amounts of ERK were loaded, an antibody against the un-
phosphorylated forms was used (lower panel).
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simultaneous presence of inhibitors. After 48 h of treatment, the me-
dium was removed and the cell morphology observed in a Leica
DRMB microscope and images captured with the Leica DC viewer
software.
3. Results
3.1. Apigenin and LY294002 sustained ERK1/2
phosphorylation and p90rsk activation in response to EGF
Exposure of serum-starved PC12 cells to EGF or NGF
caused a rapid phosphorylation of ERK1/2 (Fig. 1A). The
response elicited by EGF was transient whereas NGF showed
a sustained activation, which agreed with previous reports
[1,2]. Pre-treatment of cells for 5 min with 100 nM wortman-
nin partially blocked ERK1/2 phosphorylation stimulated by
EGF. In contrast, a similar pre-treatment with 40 WM apige-
nin or 50 WM LY294002 did not block EGF-induced ERK1/2
phosphorylation (Fig. 1B). Interestingly, the decline in the
initial phosphorylation observed in the presence of these
two inhibitors was slower than that observed with EGF alone.
It is also worth noting that although the maximal phosphor-
ylation observed in the presence of EGF plus wortmannin was
lower than that caused by EGF alone, the rate of dephosphor-
ylation was slightly slower in the presence of this PI3K inhib-
itor.
As apigenin has been reported to be a MAP kinase inhib-
itor and LY294002 is structurally related to apigenin, we
wanted to check if signalling events that led to ERK1/2 phos-
phorylation were propagated downstream. In order to do
that, we monitored the activation of p90rsk, a downstream
substrate of MAP kinase. The changes detected in p90rsk
activity were in good agreement with those expected from
the results on ERK1/2 (Fig. 2). The deactivation in the pres-
ence of apigenin and LY294002 was slower than that observed
with EGF alone reaching a plateau value between 45 and 90
min that was 50% of that attained after NGF stimulation.
Wortmannin promoted a partial blockage (40%) of the initial
activation and the rate of inactivation was similar to the one
observed with EGF.
3.2. PI3K inhibitors block PKB activation in response to EGF
or NGF
The di¡erent e¡ects on ERK1/2 activation caused by wort-
mannin and apigenin or LY294002 might re£ect di¡erences in
the cellular uptake of these compounds, which could interfere
with their ability to block the PI3K pathway. To explore this
possibility, the e¡ect of these three inhibitors on the phos-
Fig. 2. Apigenin and LY294002 promoted sustained activation of
p90rsk by EGF. PC12 cells were treated as in Fig. 1B and p90rsk
was immunoprecipitated from 200 Wg of cell lysate. 8 50 ng/ml
NGF, b 100 ng/ml EGF, R 40 WM apigenin, F 50 WM LY294002
and U 100 nM wortmannin. p90rsk activity was assayed using
crosstide as a substrate and activities are represented taking the val-
ue at 5 min after stimulation with EGF as 100%.
Fig. 3. Inhibition of PKB activity by PI3K inhibitors. PC12 cells
were not treated (lane 1) or treated with 50 ng/ml NGF (lanes 2^4)
or 100 ng/ml EGF (lanes 5^10) for the indicated times. Before the
stimulation with EGF, cells were treated for 5 min with 40 WM api-
genin (lane 8), 50 WM LY294002 (lane 9) or 100 nM wortmannin
(lane 10).
Fig. 4. E¡ect of PI3K inhibitors on Ras and Raf activity. A: Se-
rum-starved PC12 cells were untreated (Con) or treated for 2 min
with EGF (100 ng/ml), EGF plus either 40 WM apigenin, 50 WM
LY294002 or 100 nM wortmannin, or with NGF (50 ng/ml). Cells
were lysed and Ras-GTP was determined by precipitating with
GST-RBD bound to glutathione-Sepharose, followed by electropho-
resis in 12% SDS^PAGE gels and Western blotting, as indicated in
Section 2 (upper panel). Equal quantities of cell extracts were ana-
lysed by Western blot to ensure equal amounts of total Ras in the
assay (lower panel). B: Raf activity was immunoprecipitated from
cell extracts treated at the indicated times with EGF (100 ng/ml),
EGF plus either 40 WM apigenin, 50 WM LY294002 or 100 nM
wortmannin, or with NGF (50 ng/ml) and assayed in a coupled ki-
nase assay which measures the phosphorylation of MBP. Activities
are represented taking the value at 5 min after stimulation with
EGF as 100%.
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phorylation of PKB promoted by EGF and NGF was moni-
tored. Exposure of PC12 cells to either EGF or NGF pro-
moted a rapid increase in phospho-PKB, being the response
to NGF more persistent than that to EGF (Fig. 3). The si-
multaneous addition of wortmannin, apigenin or LY294002
totally blocked the appearance of phospho-PKB in response
to either EGF or NGF. This con¢rmed that the inhibitors had
reached PI3K inside the cell.
3.3. PI3K inhibitors do not a¡ect Ras and have di¡erent e¡ects
on Raf activation
The possibility that the sustained activation of ERK1/2 in
response to apigenin and LY290042 may be due to e¡ects of
these compounds on Ras or Raf was tested. No signi¢cant
e¡ects of the inhibitors were observed on EGF-induced Ras
stimulation (Fig. 4A). Raf activation attained in response to
EGF, EGF plus wortmannin or NGF was in good agreement
with the activation kinetics of ERK1/2 and p90rsk (Fig. 4B).
In contrast, neither apigenin nor LY294002 sustained EGF-
stimulated Raf activity. In fact, the presence of LY294002
resulted in a very low Raf activity at 5 min after EGF stim-
ulation. This was a surprising result in view of the sustained
activation of ERK1/2 caused by these two compounds.
3.4. The initially sustained activation of ERK1/2 is not
su⁄cient to commit PC12 cells to complete di¡erentiation
The consequences of the partially sustained ERK1/2 path-
way activation achieved by EGF plus apigenin on neurite
outgrowth were then studied. In agreement with previous re-
ports, stimulation with NGF altered cell morphology, induc-
ing in many cells the development of ¢lamentous forms 90
min after NGF addition (Fig. 5, central panels, left) whereas
the unstimulated cells showed a rounded morphology (Fig. 5,
upper panels, left). Some cells displaying protrusions and
short ¢laments were also observed after EGF treatment
(Fig. 5, upper panels, right), a fact that was more marked
when the cells were stimulated with EGF plus apigenin (Fig.
5, central panels, right). When cell cultures were allowed to
proceed for 48 h, the NGF-treated cells acquired a morphol-
ogy typical of di¡erentiated PC12 cells (Fig. 5, lower panels,
left), whereas control cells did not di¡erentiate (not shown).
Both the cells treated with EGF alone or plus apigenin
showed some short protrusions resembling collapsed initial
neurites, but the di¡erentiation process did not proceed any
further (not shown). The possibility that the lack of di¡er-
entiation was due to toxic e¡ects of apigenin is unlikely since
its presence did not a¡ect PC12 di¡erentiation induced by
NGF (Fig. 5, lower panels, right).
4. Discussion
The mechanisms underlying the di¡erent temporality of
ERK1/2 activation in response to NGF and EGF are impor-
tant questions that have been addressed by di¡erent groups by
experimental approaches [1^3] and mathematical models [17],
with controversial conclusions. In recent years it has become
evident that the PI3K pathway may a¡ect ERK1/2 activation
not only positively through Ras/c-Raf-1 [1,2], Rap/B-Raf [2,3]
or by Cdc42/RacCPakCc-Raf-1 [10], but also negatively
through inactivating phosphorylations of c-Raf and/or B-
Raf by PKB [4,5]. The results obtained in our present work
with wortmannin would agree with the hypothesis that PI3K
activity is important for maximal initial ERK1/2 activation in
response to EGF. The lack of inhibition observed on PC12
cells with the PI3K inhibitors LY294002 and apigenin is then
intriguing.
MEK phosphorylation in EGF- or NGF-stimulated PC12
cells has been estimated to be catalysed by B-Raf and c-Raf
[2]. A remarkable e¡ect shared by wortmannin, LY294002
and apigenin was the complete blockage of PKB phosphory-
lation. This fact may underlay their sustained ERK1/2 activa-
tion in response to EGF since it would favour the mainte-
nance of c-Raf and B-Raf in an activated state. However, our
data indicate that in this cell line blockage of PKB phosphor-
ylation by these compounds does not result in an increase of
Raf activity. Furthermore, the e¡ect of LY294002 and apige-
nin on EGF-induced Raf activation was markedly di¡erent in
spite of their similar e¡ects on ERK1/2 activities. The fact
that Ras activation does not change in the presence of the
three inhibitors tested suggests that the e¡ects on Raf are
not mediated solely by Ras. This also suggests that apigenin,
LY294002 and wortmannin might a¡ect di¡erent sets of cel-
lular targets. Wortmannin e¡ects on ERK1/2 activation may
Fig. 5. E¡ect of apigenin on PC12 cell di¡erentiation. PC12 were
seeded in 60 mm collagen-coated dishes and 24 h later were stimu-
lated with NGF (50 ng/ml) or EGF (100 ng/ml). Where indicated,
40 WM apigenin was added at the same time as the growth factors.
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be explained through changes in Raf activity whereas those of
apigenin and LY294002 would require other unde¢ned com-
ponents which may in£uence ERK1/2 phosphorylation/de-
phosphorylation processes. A lack of correlation between
Raf activity and ERK1/2 phosphorylation has been reported
previously by others [18]. In any case, the data clearly indicate
that in this cell line apigenin does not act as an inhibitor of
ERK1/2 since a sustained activation of p90rsk, a downstream
target of ERK1/2 was observed in its presence and it did not
block the di¡erentiation induced by NGF.
Maintenance of ERK1/2 activation for periods longer than
those achieved with EGF alone induced mid-term morpholog-
ical alterations of PC12 similar to those caused by NGF.
However this was not su⁄cient to prime the cells to complete
the di¡erentiation process. Interestingly, overexpression of
RapN17, a dominant negative mutant of Rap1, that did not
a¡ect the initial rapid activation of ERK1/2 in response to
NGF but abolished the maintenance of ERK1/2 in the acti-
vated state, did not inhibit neurite outgrowth [19]. Thus, it has
been suggested that NGF-induced di¡erentiation of PC12
cells might involve additional events that occur at later stages
and are triggered through PI3K-dependent pathways [11,19].
In any case, the fact that apigenin did not block NGF-in-
duced di¡erentiation under conditions that prevent PKB
phosphorylation argues against a prominent role of the
PKB pathway in triggering PC12 di¡erentiation.
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